Barinthus Biotherapeutics (BRNS)

• Market cap: $39.4M
• 1 day: -5.77%
• 5 days: 3.16%
• 1 month: -15.52%
• 3 months: -26.32%
• 6 months: -32.41%
• Year to date: -20.97%
• 1 year: -67.87%
• 5 years: -93.05%
• 10 years: -93.05%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Employees: 130

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

6% more funds holding

Funds holding: 18 [Q2] → 19 (+1) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.61% less ownership

Funds ownership: 25.43% [Q2] → 24.82% (-0.61%) [Q3]

9% less capital invested

Capital invested by funds: $11.8M [Q2] → $10.7M (-$1.03M) [Q3]

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 206% upside
• Avg. target: $3 206% upside
• High target: $3 206% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 38% 1-year accuracy 59 / 156 met price target

206% upside $3

Buy Maintained

13 Jan 2025